SU4942 is primarily utilized in research settings as a selective inhibitor of fibroblast growth factor receptor (FGFR) tyrosine kinase. It plays a significant role in studying cellular signaling pathways, particularly those involved in angiogenesis and tumor growth. Researchers use SU4942 to investigate the mechanisms of FGFR-dependent processes in cancer biology, helping to identify potential therapeutic targets for cancer treatment. Additionally, it aids in understanding the role of FGFR in developmental biology and tissue regeneration. Its application extends to preclinical studies where it is used to evaluate the efficacy of FGFR inhibition in various disease models, contributing to the development of novel anticancer drugs.